Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Efficacy of Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Toxicities - a Multicenter Retrospective Analysis

Amneet K Bajwa, Qiuhong Zhao, Marcus Johannes Geer, Agrima Mian, Chenyu Lin, David Frame, James Westholder, Justin Tossey, Monalisa Ghosh, Ahmed Galal, Nausheen Ahmed, Joseph E. Maakaron, Nathan Denlinger, Marcos de Lima, Narendranath Epperla, Paolo F. Caimi, Timothy Voorhees

Blood (2023) 142 (Supplement 1): 4502.

https://doi.org/10.1182/blood-2023-179620

Published: 2023

Journal Articles

Lymphodepleting Chemotherapy before CD19 Directed CAR T-Cell Therapy: Are 3 Days Necessary?

Marcus Geer, Salena Kasha, David Frame, Monalisa Ghosh

Blood (2022) 140 (Supplement 1): 3823–3824.

https://doi.org/10.1182/blood-2022-168456

Published: 2022

Journal Articles

Defibrotide Therapy for Sars CoV2 Acute Respiratory Distress Syndrome

Gregory A Yanik, David Frame, Gianni Bruno Scappaticci, Mary Maliarik, Steven W Pipe, Thomas Braun, Thomas Sisson, Paul G. Richardson, Daniel A Lawrence, Vibha Lama

Blood (2021) 138 (Supplement 1): 3237.

https://doi.org/10.1182/blood-2021-151417

Published: 2021

Journal Articles

A Multi-Center Case Series, Systematic Review and Meta-Analysis of Neonatal Hemophagocytic Lymphohistiocytosis

Christen L. Ebens, MDMPH, Adam S DuVall, MD, Todd E. DeFor, MS, Marketa T. Dimitrov, MD, David Frame, Michael A. Briones, Michael Grimley, MD, Sarita Joshi, MBBS,MD, Rebecca A. Marsh, Evan Shereck, MD, Mark Vander Lugt, MD, James A. Connelly, MD, Kelly J. Walkovich, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-142895

Published: 2020

Journal Articles

Phase 1 Study of Carfilzomib for the Prevention of Relapse and Graft-Versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Attaphol Pawarode, MD, Steven Goldstein, MD, Daniel R. Couriel, MD, Thomas Braun, PhD, John M. Magenau, MD, Mary Mansour Riwes, DO, Brian Parkin, Vedran Radojcic, MD, David Frame, PharmD, Sung Choi, MD, James Connelly, MD, John E. Levine, MD MS, Gregory A. Yanik, MD, Pavan Reddy, MD

Blood (2015) 126 (23): 1907.

https://doi.org/10.1182/blood.V126.23.1907.1907

Published: 2015

Journal Articles

Baseline Body Mass Index Among Children and Adults Undergoing Allogeneic Hematopoietic Cell Transplantation: Clinical Characteristics and Outcomes

Michael Gleimer, PhD, Yumeng Li, MS, Lawrence Chang, MS, MD, Sophie Paczesny, MD PhD, David Hanauer, MS, MD, David Frame, PhD, Craig A. Byersdorfer, MD PhD, Pavan Reddy, MD, Thomas M. Braun, PhD, Sung Won Choi, MS, MD

Blood (2014) 124 (21): 2558.

https://doi.org/10.1182/blood.V124.21.2558.2558

Published: 2014

Journal Articles

Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies

Blood (2011) 118 (15): 4258–4264.

https://doi.org/10.1182/blood-2011-06-358010

Published: 2011

Includes: Supplemental data

Journal Articles

The Risk Factor Assessment Score and Incidence of Venous Thromboembolism In 629 Patients Undergoing Hematopoietic Stem Cell Transplantation Implications for VTE Prophylaxis

Edward M. Peres, MD, Alex Orman, PhD, Shin Mineishi, Denise Markstrom, PhD, Paula Bockenstedt, PhD, David Frame, PhD

Blood (2010) 116 (21): 4215.

https://doi.org/10.1182/blood.V116.21.4215.4215

Published: 2010

Journal Articles

Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.

Shin Mineishi, MD, John Magenau, MD, Attaphol Pawarode, MD, Timothy Buck, Dawn Jones, RN, Koji Kato, MD, David Frame, Pharm.D, Lisa Kujawski, MD, Harry Paul Erba, MD, PhD, Yasser Khaled, MD, Edward M. Peres, MD, Oleg I. Krijanovski, PhD, MD, Pavan Reddy, MD, Carrie Kitko, MD, Sung Choi, MD, Gregory A. Yanik, MD, Thomas Braun, PhD, James L.M. Ferrara, MD, John E. Levine, MD

Blood (2008) 112 (11): 2150.

https://doi.org/10.1182/blood.V112.11.2150.2150

Published: 2008

NARROW

Efficacy of Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Toxicities - a Multicenter Retrospective Analysis

Lymphodepleting Chemotherapy before CD19 Directed CAR T-Cell Therapy: Are 3 Days Necessary?

Defibrotide Therapy for Sars CoV2 Acute Respiratory Distress Syndrome

A Multi-Center Case Series, Systematic Review and Meta-Analysis of Neonatal Hemophagocytic Lymphohistiocytosis

Phase 1 Study of Carfilzomib for the Prevention of Relapse and Graft-Versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Baseline Body Mass Index Among Children and Adults Undergoing Allogeneic Hematopoietic Cell Transplantation: Clinical Characteristics and Outcomes

Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies

The Risk Factor Assessment Score and Incidence of Venous Thromboembolism In 629 Patients Undergoing Hematopoietic Stem Cell Transplantation Implications for VTE Prophylaxis

Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only